Supplemental Online Content

Montalvan-Sanchez EE, Norwood DA, Dougherty M, et al. Colorectal Cancer Screening Programs in Latin America. *JAMA Netw Open.* 2024;7(2):e2354256. doi:10.1001/jamanetworkopen.2023.54256

eTable 1. Search Strategy

eFigure 1. Flow Diagram of Study Inclusion

eTable 2. Excluded Studies and Reasons for Exclusion

eTable 3. Risk of Bias Using the New Castle Ottawa Scale for Comparative Studies

eTable 4. Strategies for Sampling and Recruitment of Included Studies

eTable 5. Univariate Meta Regression

eFigure 2. Participation Rate (FIT Given/FIT Returned) by Region

eFigure 3. Participation Rate (FIT Given/FIT Returned) by Recruitment Strategy

eFigure 4. Participation Rate (FIT Given/FIT Returned) by Sample Size

eFigure 5. Colonoscopy Follow-Up (Colonoscopies Performed After a Positive FIT Test)

eFigure 6. Outcome ADR (Adenoma Detection Rate) Per Positive FIT Test in FIT Based Programs

eFigure 7. Outcome AADR (Advanced Adenomas Detection Rate) Per Positive FIT Test in FIT Based Programs

eFigure 8. Outcome CRCDR (Colorectal Cancer Detection Rate) Per Positive FIT Test in FIT Based Programs

eFigure 9. Yield of Colonoscopy: AADR (Advanced Adenomas Detection Rate). FIT Programs

eFigure 10. Yield of Colonoscopy: AADR (Advanced Adenomas Detection Rate). Direct-to-Colonoscopy Programs

eFigure 11. Yield of Colonoscopy: CRC-DR (Adenocarcinoma Detection Rate) by Type of Program

eFigure 12. Colonoscopy Quality Indicators: Cecal Intubation Rate

eFigure 13. Colonoscopy Quality Indicators: Mean Withdrawal Time from cecum (mean, minutes)

eFigure 14. Colonoscopy Quality Indicators: Adequate Bowel Preparation

eFigure 15. Heterogeneity and Publication bias (small study effects) for FIT Based Studies

eFigure 16. Heterogeneity and Publication Bias (Small Study Effects) for Outcomes Per Positive FIT Test in FIT Based Programs

eFigure 17. Heterogeneity and Publication Bias (Small Study Effects) for Outcomes in Direct-to-Colonoscopy Programs

eFigure 18. Heterogeneity and Publication Bias (Small Study Effects) for Colonoscopy Quality Indicators

eFigure 19. ADR (Adenomas Detection Rate) FIT Programs by Risk: Leave-One-Out Analysis

eFigure 20. ADR (Adenomas Detection Rate) FIT Programs by FIT Cut-Off: Leave-One-Out Analysis

eFigure 21. CRC (Adenocarcinoma Detection Rate) FIT Programs: Leave-One-Out Analysis

eFigure 22. ADR (Adenomas Detection Rate) FIT Programs: Leave-One-Out Analysis

eFigure 23. AADR (Advanced Adenomas Detection Rate) FIT programs: Leave-One-Out Analysis

eFigure 24. CRC (Adenocarcinoma Detection Rate) FIT Programs: Leave-One-Out Analysis

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable1. Search Strategy

Database	Search Strategy	Result
Medline (OVID)	1 exp colonoscopy/ 2 "Colonography, Computed Tomographic"/ 3 "occult blood"/ 4 colonoscop*.ti,ab,kf. 5 colonograph*.ti,ab,kf. 6 sigmoidoscop*.ti,ab,kf. 7 ((colon or colorectal or colo-rectal or colonic or anal or anus or bowel or rectocolonic* or rectal or rectum or sigmoid*) adj3 (endoscop* or tomograph*)).ti,ab,kf. 8 ((occult or hidden) adj3 (blood or bleeding or haemorrhag* or hemorrhag*)).ti,ab,kf. 9 ((stool or fecal or faecal or faeces or feces) adj3 blood).ti,ab,kf. 10 hemoccult.ti,ab,kf. 11 (FOB or FOBT* or gFOBT* or iFOBT*).ti,ab,kf. 12 ((stool or fecal or faecal or faeces or feces) adj5 (immunologic* or immunochem*)).ti,ab,kf. 13 ((stool or guaiac or guajac or guaiacum) adj5 (test or sample*)).ti,ab,kf. 14 (((stool or fecal or faecal or faeces or feces) adj3 (DNA or sDNA)) or "sDNA-FIT").ti,ab,kf. 15 or/1-14 16 exp Colorectal Neoplasms/ 17 Colonic Polyps/ 18 exp Colonic Diseases/ 19 ((colon or colorectal or colo-rectal or colonic or anal or anus or bowel or rectocolonic* or rectal or rectum or sigmoid) adj5 (cancer* or carcinogen* or neoplasm* or neoplasia or neoplastic or adenoma* or adenocarcinoma* or polyp or polyps or carcinoma* or malignan* or tumor* or tumour* or precancer* or premalignan*)).ti,ab,kf. 20 or/16-19 21 Mass Screening/ 22 Early Detection of Cancer/ 23 Early Diagnosis/ 24 (screening* or screened or screens).ti,ab,kf. 25 ((early* or earlier or prevent*) adj5 (assessment or detect* or diagnos* or discover* or evaluat* or exam* or onset or stage*)).ti,ab,kf. 26 or/21-25 27 (CRC adj3 (assessment* or screen* or detect* or diagnos* or discovery or exam* or endoscop*)).ti,ab,kf. 28 (15 or 20) and 26 29 27 or 28 30 ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or	Run on April 30, 2022, 664 citations retrieved. Rerun on February 27, 2023, 43 citations retrieved.

	"Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies").tw,xm,kf. 31 29 and 30	
Embase (Elsevier)	#1 'colonoscopy'/exp #2 'colonography, computed tomographic'/de #3 'sigmoidoscopy'/de #4 'occult blood'/de #5 colonoscop*:ti,ab,kw #6 colonograph*:ti,ab,kw #7 sigmoidoscop*:ti,ab,kw #8 ((colon OR colorectal OR 'colo rectal' OR colonic OR anal OR anus OR bowel OR rectocolonic* OR rectal OR rectum OR sigmoid*) NEAR/3 (endoscop* OR tomograph*)):ti,ab,kw #9 ((occult OR hidden) NEAR/3 (blood OR bleeding OR haemorrhage* OR hemorrhage*)):ti,ab,kw #10 ((stool OR fecal OR faecal OR faeces OR feces) NEAR/3 blood):ti,ab,kw #11 hemoccult:ti,ab,kw #12 fob:ti,ab,kw OR fobt*:ti,ab,kw OR gfobt*:ti,ab,kw OR ifobt*:ti,ab,kw #13 ((stool OR fecal OR faecal OR faeces OR feces) NEAR/5 (immunologic* OR immunochem*)):ti,ab,kw #14 ((stool OR guaiac OR guajac OR guaiacum) NEAR/5 (test OR sample*)):ti,ab,kw #15 (((stool OR fecal OR faecal OR faeces OR feces) NEAR/3 (dna OR 'stool sdna')):ti,ab,kw) OR 'sdna fit':ti,ab,kw #16 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 #17 'colon cancer'/exp #18 'colon tumor'/exp #19 'colorectal tumor'/exp #20 'colon polyp'/exp #21 'colon disease'/de #22 ((colon OR colorectal OR 'colo rectal' OR colonic OR anal OR anus OR bowel OR rectocolonic* OR rectal OR rectum OR sigmoid) NEAR/5 (cancer* OR carcinogen* OR neoplasm* OR neoplasia OR neoplastic OR adenoma* OR adenocarcinoma* OR polyp OR polyps OR carcinoma* OR malignan* OR tumor* OR tumour* OR precancer* OR premalignan*)):ti,ab,kw #23 #17 OR #18 OR #19 OR #20 OR #21 OR #22 #24 'screening'/de #25 'screening test'/de #26 'mass screening'/de #27 'early cancer diagnosis'/de #28 'early diagnosis'/de #29 'cancer diagnosis'/de #30 screening*:ti,ab,kw OR screened:ti,ab,kw OR screens:ti,ab,kw #31 ((early* OR earlier OR prevent*) NEAR/5 (assessment OR detect* OR diagnos* OR discover* OR evaluat* OR exam* OR onset OR stage*)):ti,ab,kw #32 #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR 31 #33 ('crc' NEAR/3 (assessment* OR screen* OR detect* OR diagnos* OR discovery OR exam* OR endoscop*)):ti,ab,kw #34 (#16 OR #23) AND #32 #35 #33 OR #34 #36 'south and central america'/exp	Run on April 30, 2022, 1992 citations retrieved. Rerun on February 27, 2023, 188 citations retrieved.

	#37 'caribbean islands'/exp #38 'mexico'/exp #39 'antigua and barbuda':ti,ab,kw OR 'antigua & barbuda':ti,ab,kw OR argentin*:ti,ab,kw OR aruba:ti,ab,kw OR bahamas:ti,ab,kw OR barbados:ti,ab,kw OR belize:ti,ab,kw OR belice:ti,ab,kw OR bolivia*:ti,ab,kw OR brazil*:ti,ab,kw OR brasil*:ti,ab,kw OR caribbean*:ti,ab,kw OR 'cayman islands':ti,ab,kw OR 'central america*':ti,ab,kw OR chile:ti,ab,kw OR chilean*:ti,ab,kw OR colombia*:ti,ab,kw OR 'costa rica*':ti,ab,kw OR cuba:ti,ab,kw OR cuban*:ti,ab,kw OR curacao:ti,ab,kw OR dominica*:ti,ab,kw OR 'dominican republic':ti,ab,kw OR ecuador*:ti,ab,kw OR salvador:ti,ab,kw OR salvadorian*:ti,ab,kw OR 'french guiana':ti,ab,kw OR grenada:ti,ab,kw OR guadeloupe:ti,ab,kw OR guatemala*:ti,ab,kw OR guyana:ti,ab,kw OR haiti*:ti,ab,kw OR honduras:ti,ab,kw OR honduran*:ti,ab,kw OR jamaica*:ti,ab,kw OR 'latin america*':ti,ab,kw OR latinoamerican*:ti,ab,kw OR latinamerican*:ti,ab,kw OR martinique:ti,ab,kw OR mexico:ti,ab,kw OR mexican*:ti,ab,kw OR nicaragua*:ti,ab,kw OR panama*:ti,ab,kw OR paraguay*:ti,ab,kw OR peru:ti,ab,kw OR peruvian*:ti,ab,kw OR 'puerto ric*':ti,ab,kw OR boricua*:ti,ab,kw OR salvadoran*:ti,ab,kw OR 'sint maarten':ti,ab,kw OR 'south america*':ti,ab,kw OR 'kitts & nevis':ti,ab,kw OR 'kitts and nevis':ti,ab,kw OR 'saint lucia':ti,ab,kw OR 'st. lucia':ti,ab,kw OR 'saint martin':ti,ab,kw OR 'st. martin':ti,ab,kw OR 'vincent and the grenadines':ti,ab,kw OR 'vincent & the grenadines':ti,ab,kw OR surinam*:ti,ab,kw OR 'trinidad and tobago':ti,ab,kw OR 'trinidad & tobago':ti,ab,kw OR 'turks and caicos':ti,ab,kw OR 'turks & caicos':ti,ab,kw OR uruguay*:ti,ab,kw OR venezuela*:ti,ab,kw OR 'virgin islands':ti,ab,kw OR 'west indies':ti,ab,kw #40 #36 OR #37 OR #38 OR #39 #41 #35 AND #40	
Google Scholar	allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) (America|"Antigua and Barbuda"|Argentina|Aruba|Brasil|Brazil) allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) (Bahamas|Barbados|Belize|Belice|Bolivia|Caribbean|"Cayman Islands") allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) (Chile|Colombia|"Costa Rica"| Cuba|Curacao|Dominica|Dominican) allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) (Ecuador|Grenada|Guadeloupe|Guatemala|Guyana|Guiana) allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|ea	Run on April 30, 2022, 119 citations retrieved after deduplication. Rerun on February 27, 2023, 16 citations retrieved.

	rly|temprano|temprana) (Haiti|Honduras|Jamaica|Martinique|Mexico|Nicaragua|Panama|Paraguay|Peru) allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) ("Puerto Rico"|Salvador|Suriname|Uruguay|Sint-Maarten|Kitts|Nevis) allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) (Lucia|Saint Martin|Grenadines|Trinidad|Tobago) allintitle: (CRC|colorectal|colon|colorrectal|colonoscopy|colonoscopia) (screening|tamizaje| tamizar|tamizacion|rastreo|rastreamento|preventive|prevention|prevencion|early|temprano|temprana) (Turks|Caicos|Uruguay|Venezuela|"Virgin Islands"|"West Indies")	
LILACS	LILACS https://lilacs.bvsalud.org/en/ ("Cancer of Colon" OR "Cancer of the Colon" OR "Colon Cancer" OR "Colon Cancers" OR "Colon Neoplasm" OR "Colon Neoplasms" OR "Colonic Cancer" OR "Colonic Cancers" OR "Colonic Neoplasm" OR "Colonic Neoplasms" OR "Colorectal Cancer" OR "Colorectal Cancers" OR "cancer Colorrectal" OR "Colorectal adenocarcinoma" OR "adenocarcinoma colorectal" OR "adenocarcinoma colorretais" OR "colon adenocarcinoma" OR "adenocarcinoma de colon" OR "cancer Colorretal" OR "Colorectal Carcinoma" OR "Colorectal Carcinomas" OR "Carcinoma Colorrectal" OR "Carcinomas Colorectales" OR "Colorectal Neoplasm" OR "Colorectal Neoplasms" OR "Colorectal Neoplasias" OR "Neoplasms Colorectal" OR "Neoplasia Colorrectal" OR "Neoplasia Colorretal" OR "Neoplasias del Colon" OR "Neoplasias Colorretais" OR "Rectal neoplasm" OR "Rectal neoplasms" OR "Cancer of Rectum" OR "Cancer of the Rectum" OR "Rectal Cancer" OR "Rectal Cancers" OR "Rectal Tumor" OR "Rectal Tumors" OR "Rectum Cancer" OR "Rectum Cancers" OR "Rectum Neoplasm" OR "Rectum Neoplasms" OR " Neoplasias del Recto" OR "Neoplasias retais" OR "Colorectal Tumor" OR "Colorectal Tumors" OR "Anal Cancer" OR "Anal Cancers" OR "Anal Neoplasm" OR "Anal Neoplasms" OR "Anus Cancer" OR "Anus Cancers" OR "Anus Neoplasm" OR "Cancer of Anus" OR "Cancer of the Anus" OR "Neoplasias del Ano" OR "Neoplasias do Anus" OR "Neoplasias do Anus" OR "Tumor colorrectal" OR "Tumores colorrectales" OR "Neoplasias do Colo Sigmoide" OR "Cancer of Sigmoid" OR "Cancer of the Sigmoid" OR "Sigmoid Cancer" OR "Sigmoid Colon Cancer" OR "Sigmoid Neoplasm" OR "Sigmoidal Cancer" OR "Colonic Polyps" OR "Polipos del Colon" OR "Colonic Polyp" OR "Polipos do Colo" OR Colonoscopy OR Colonoscopia OR Colonography OR Colonografia OR Sigmoidoscopy OR "occult blood" OR "sangre oculta" OR "sangre en las heces" OR "sangre escondida" OR "sangue escondido" OR "Sangue Oculto" OR "sangue nas fezes" OR "Fecal Immunochemical" OR "inmunoquimica fecal" OR "stool DNA" OR sDNA OR "sDNA-FIT" OR hemoccult OR FOBT OR gFOBT OR iFOBT OR guaiac OR guajac OR guaiacum) AND (screening OR screenings OR tamizaje OR tamizar OR tamizacion OR rastreo OR rastreamento or rastreio OR "early detection" OR "deteccion temprana" OR "Deteccion Precoz" OR "Detecção Precoce" OR "early	Run on April 30, 2022, 1536 citations retrieved. Rerun on February 27, 2023, 40 citations retrieved.

	diagnosis" OR "diagnostico temprano" OR "Diagnostico Precoce" OR "early onset" OR "early assessment" OR "revision temprana" OR "chequeo temprano" OR "revision temprana" OR "revisao precoce" OR "early discovery" OR "descubrimiento temprano" OR "descoberta precoce" OR "avaliacao precoce" OR "preventive examination" OR "preventive evaluation" OR "evaluacion temprana" OR "evaluacion preventiva" OR "evaluacion temprana" OR "exames preventivos")	
PsycINFO 1887-current (EBSCO)	S1 colonoscop* OR colonograph* OR sigmoidoscop* S2 ((colon OR colorectal OR colo-rectal OR colonic OR anal OR anus OR bowel OR rectocolonic* OR rectal OR rectum OR sigmoid*) N3 (endoscop* OR tomograph*)) S3 ((occult OR hidden) N3 (blood OR bleeding OR haemorrhage* OR hemorrhage*)) S4 ((stool OR fecal OR faecal OR faeces OR feces) N3 blood) S5 hemoccult S6 (FOB OR FOBT* OR gFOBT* OR iFOBT*) S7 ((stool OR fecal OR faecal OR faeces OR feces) N5 (immunologic* OR immunochem*)) S8 ((stool OR guaiac OR guajac OR guaiacum) N5 (test OR sample*)) S9 (((stool OR fecal OR faecal OR faeces OR feces) N3 (DNA OR sDNA)) OR sDNA-FIT) S10 (S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9) S11 ((colon OR colorectal OR colo-rectal OR colonic OR anal OR anus OR bowel OR rectocolonic* OR rectal OR rectum OR sigmoid) N5 (cancer* OR carcinogen* OR neoplasm* OR neoplasia OR neoplastic OR adenoma* OR adenocarcinoma* OR polyp OR polyps OR carcinoma* OR malignan* OR tumor* OR tumour* OR precancer* OR premalignan*)) S12 (screening* OR screened OR screens) S13 ((early* OR earlier OR prevent*) N5 (assessment OR detect* OR diagnos* OR discover* OR evaluat* OR exam* OR onset OR stage*)) S14 S12 OR S13 S15 (CRC N3 (assessment* or screen* or detect* or diagnos* or discovery or exam* or endoscop*)) S16 (S10 OR S11) AND S14 S17 S15 OR S16 S18 TI ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or "Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies") OR SU ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or	Run on April 30, 2022, 57 citations retrieved. Rerun on February 27, 2023, 1 citation retrieved

	Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or "Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies") OR PL ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or "Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies") OR AB ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or "Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies") OR KW ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or "Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies") S19 (S17 AND S18)	
SciELO	("Cancer of Colon" OR "Cancer of the Colon" OR "Colon Cancer" OR "Colon Cancers" OR "Colon Neoplasm" OR "Colon Neoplasms" OR "Colonic Cancer" OR "Colonic Cancers" OR "Colonic Neoplasm" OR "Colonic Neoplasms" OR "Colorectal Cancer" OR "Colorectal Cancers" OR "cancer	Run on April 29, 2022, 362 citations

	Colorrectal" OR "Colorectal adenocarcinoma" OR "adenocarcinoma colorectal" OR "adenocarcinoma colorretais" OR "colon adenocarcinoma" OR "adenocarcinoma de colon" OR "cancer Colorretal" OR "Colorectal Carcinoma" OR "Colorectal Carcinomas" OR "Carcinoma Colorrectal" OR "Carcinomas Colorectales" OR "Colorectal Neoplasm" OR "Colorectal Neoplasms" OR "Colorectal Neoplasias" OR "Neoplasms Colorectal" OR "Neoplasia Colorrectal" OR "Neoplasia Colorretal" OR "Neoplasias del Colon" OR "Neoplasias Colorretais" OR "Rectal neoplasm" OR "Rectal neoplasms" OR "Cancer of Rectum" OR "Cancer of the Rectum" OR "Rectal Cancer" OR "Rectal Cancers" OR "Rectal Tumor" OR "Rectal Tumors" OR "Rectum Cancer" OR "Rectum Cancers" OR "Rectum Neoplasm" OR "Rectum Neoplasms" OR " Neoplasias del Recto" OR "Neoplasias retais" OR "Colorectal Tumor" OR "Colorectal Tumors" OR "Anal Cancer" OR "Anal Cancers" OR "Anal Neoplasm" OR "Anal Neoplasms" OR "Anus Cancer" OR "Anus Cancers" OR "Anus Neoplasm" OR "Cancer of Anus" OR "Cancer of the Anus" OR "Neoplasias del Ano" OR "Neoplasias do Anus" OR "Neoplasias do Anus" OR "Tumor colorrectal" OR "Tumores colorrectales" OR "Neoplasias do Colo Sigmoide" OR "Cancer of Sigmoid" OR "Cancer of the Sigmoid" OR "Sigmoid Cancer" OR "Sigmoid Colon Cancer" OR "Sigmoid Neoplasm" OR "Sigmoidal Cancer" OR "Colonic Polyps" OR "Polipos del Colon" OR "Colonic Polyp" OR "Polipos do Colo" OR Colonoscopy OR Colonoscopia OR Colonography OR Colonografia OR Sigmoidoscopy OR "occult blood" OR "sangre oculta" OR "sangre en las heces" OR "sangre escondida" OR "sangue escondido" OR "Sangue Oculto" OR "sangue nas fezes" OR "Fecal Immunochemical" OR "inmunoquimica fecal" OR "stool DNA" OR sDNA OR "sDNA-FIT" OR hemoccult OR FOBT OR gFOBT OR iFOBT OR guaiac OR guajac OR guaiacum) AND (screening OR screenings OR tamizaje OR tamizar OR tamizacion OR rastreo OR rastreamento or rastreio OR "early detection" OR "deteccion temprana" OR "Deteccion Precoz" OR "Detecção Precoce" OR "early diagnosis" OR "diagnostico temprano" OR "Diagnostico Precoce" OR "early onset" OR "early assessment" OR "revision temprana" OR "chequeo temprano" OR "revision temprana" OR "revisao precoce" OR "early discovery" OR "descubrimiento temprano" OR "descoberta precoce" OR "avaliacao precoce" OR "preventive examination" OR "preventive evaluation" OR "evaluacion temprana" OR "evaluacion preventiva" OR "evaluacion temprana" OR "exames preventivos")	retrieved. Rerun on February 27, 2023, 25 citations retrieved
Web of Science Core Collection	((((TS=(colonoscop* OR colonograph* OR sigmoidoscop*) OR TS=((colon OR colorectal OR colo-rectal OR colonic OR anal OR anus OR bowel OR rectocolonic* OR rectal OR rectum OR sigmoid*) NEAR/3 (endoscop* OR tomograph*)) OR TS=((occult OR hidden) NEAR/3 (blood OR bleeding OR haemorrhage* OR hemorrhage*)) OR TS=((stool OR fecal OR faecal OR faeces OR feces) NEAR/3 blood) OR TS=hemoccult OR TS=(FOB OR FOBT* OR gFOBT* OR iFOBT*)) OR TS=((colon OR colorectal OR colo-rectal OR colonic OR anal OR anus OR bowel OR rectocolonic* OR rectal OR rectum OR sigmoid) NEAR/5 (cancer* or carcinogen* or neoplasm* or neoplasia or neoplastic or adenoma* or adenocarcinoma* or polyp or polyps or carcinoma* or malignan* or tumor* or tumour* or precancer* or premalignan*)))) AND (TS=(screening* OR screened OR screens) OR TS=((early* OR earlier OR prevent*) NEAR/5 (assessment or detect* or diagnos* or discover* OR evaluat* OR exam* or onset or stage*assessment or detect* or diagnos* or discover* or exam* or onset or stage*))) OR TS=(CRC NEAR/3 (assessment* or screen* or detect* or diagnos* or discovery or exam* or endoscop*))) AND TS= ("Antigua and Barbuda" or "Antigua & Barbuda" or Argentin* or Aruba or Bahamas or Barbados or Belize or Belice or Bolivia* or Brazil* or Brasil* or Caribbean* or "Cayman Islands" or central-	Run on April 28, 2022, 581 citations retrieved. Rerun on February 27, 2023, 37 citations retrieved

	america* or Chile or chilean* or Colombia* or "Costa Rica*" or Cuba or cuban* or Curacao or Dominica* or "Dominican Republic" or Ecuador* or Salvador or Salvadorian* or French-Guiana or Grenada or Guadeloupe or Guatemala* or Guyana or Haiti* or Honduras or honduran* or Jamaica* or Latin-america* or latinoamerican* or latinamerican* or Martinique or Mexico or mexican* or Nicaragua* or Panama* or Paraguay* or Peru or Peruvian* or Puerto-ric* or boricua* or Salvadoran* or Sint-Maarten or south-america* or "Kitts & Nevis" or "Kitts and Nevis" or "Saint Lucia" or "St. Lucia" or "Saint Martin" or "St. Martin" or "Vincent and the Grenadines" or "Vincent & the Grenadines" or Surinam* or "Trinidad and Tobago" or "Trinidad & Tobago" or "Turks and Caicos" or "Turks & Caicos" or Uruguay* or Venezuela* or "Virgin Islands" or "West Indies")	

eFigure 1. Flow Diagram of Study Inclusion



eTable 2. Excluded studies and reasons for exclusion.

Bandres D, Yanes E, Caravajal A, et al. Results of a large screening program for colonic polyps and colon cancer using flexible sigmoidoscopy in Venezuela. *Gastroenterology*. 1997;112(4):A535-A535.
Reason for exclusion: Wrong study design
Bravo Hernández N, Gómez Lloga T, Noa Garbey M, Quevedo Navarro AL, Gómez Lloga R. Pesquisa de cáncer de colon en grupos de riesgos del Policlínico Universitario "Omar Ranedo Pubillones de Guantánamo. *Revista Información Científica*. 2018;97(1):95-105.
Reason for exclusion: Wrong study design
Carballo EN, Melendez FDH. Prevalence of advanced colorectal neoplasia according to risk categories at screening colonoscopy in a tertiary referral center. *Journal of Clinical Oncology*. 2018;36(4)doi:10.1200/JCO.2018.36.4-suppl.578
Reason for exclusion: Wrong study design
Casal ER, Velázquez EN, Mejía RM, Cuneo A, Pérez-Stable EJ. Rastreo del cáncer colorrectal: Conocimiento y actitud de la población. *Medicina (BAires)*. 2009;69(1):135-142.
Reason for exclusion: Wrong study design
Cawich SO, Phillips E, Moore S, Ramkissoon S, Padmore G, Griffith S. Colorectal cancer in an Eastern Caribbean nation: are we missing an opportunity for secondary prevention? *Revista Panamericana de Salud Pública*. 2022;46
Reason for exclusion: Wrong study design
Chandra A, Cooper E. Colorectal cancer in the bahamian population. *American Journal of Gastroenterology*. 2014;109:S618. doi:10.1038/ajg.2014.285
Reason for exclusion: Different outcome
Coughlin SS, Lubetkin EI, Hay JL, Raphael R, Smith SA. Promoting colorectal cancer screening among Haitian Americans. *Journal of the Georgia Public Health Association*. 2015;5(2):149-152.
Reason for exclusion: Wrong study design
Estefanía D, Tyrrell C, Bugallo F, et al. Pesquisa del cáncer colorrectal en un hospital de comunidad: experiencia, resultados y eficacia del método. *Rev argent coloproctología*. 2011;22(1):10-15.
Reason for exclusion: Wrong study design

Fernandez JL, Gallegos M, Brochero A, Arevalo C, Piccioni H, Gutierrez Galiana H. [Screening for colorectal cancer with an immunological fecal occult blood test]. *Pesquisa del cancer colorrectal con una prueba inmunologica para sangre oculta en material fecal*. 1999;29(2):73-8.
Reason for exclusion: Wrong study design
Garza AA, Becerra CA, Gonzalez-Gonzalez JA, et al. Colorectal cancer screening in Mexico: The first one hundred patients. *American Journal of Gastroenterology*. 2006;101(9):S559-S559. doi:10.14309/00000434-200609001-01471
Reason for exclusion: Wrong study design
Jimenez G, Perez MdlA, Vega H, Hano O. Pesquisaje de lesiones precancerosas y cancerosas del colon en los trabajadores del asbesto. *Rev cuba hig epidemiol*. 1995;33(1/2):25-30.
Reason for exclusion: Different patient population
Kennedy LS, Marra KA, Marshall LaRochelle EP, et al. Cancer screening in rural Honduras: Maximizing impact with a multiorgan screening approach. *Cancer Epidemiology Biomarkers and Prevention*. 2018;27(7)doi:10.1158/1538-7755.DISP17-B20
Reason for exclusion: Wrong study design
Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial. *Archives of Internal Medicine*. 2011;171(10):906-12. doi:10.1001/archinternmed.2011.201
Reason for exclusion: Wrong study design
Lathroum L, Ramos-Mercado F, Villafana M, Cruz-Correa MR. Prevalence of colorectal neoplasia in asymptomatic hispanics undergoing screening colonoscopy. *Gastrointestinal Endoscopy*. 2010;71(5):AB194. doi:10.1016/j.gie.2010.03.333
Reason for exclusion: Wrong study design
Lopez-Kostner F, Fullerton DA, Kronberg U, et al. Screening colonoscopy among first degree relatives of patients with colorectal carcinoma. *Revista Medica De Chile*. 2006;134(8):997-1001.
Reason for exclusion: Different patient population
Montano D, Fenocchi Môneda ER, Martínez Gómez L, Tolve Tilbe JA, Rondán Olivera M. Programa de Screening en cáncer colo-rectal. *Cir Urug*. 2005;75(3):180-188.
Reason for exclusion: Wrong study design
Montano Morgade DE, Fenocchi Moneda ER, Martínez Gómez L, Rondán Olivera M, Olano Gossweiler AC. Screening en cáncer colorrectal. Primer estudio de población asintomática en Uruguay. *Cir Urug*. 2000:14-9.
Reason for exclusion: Duplicate data

Nery TDD, Hara EKM, Feijo CD, et al. Occupational Health As a Tool to Improve Workers' Health. Experience Report in Colorectal Cancer Screening in the Approach of 12,233 Professionals in the Largest Hospital Complex in Latin America. *Safety and Health at Work*. 2022;13:S235-S235.
Reason for exclusion: Wrong study design
Pagan-Torres H, Borrero WM, Soto M, Cruz-Correa MR. EVALUATION OF THE DISSEMINATION AND IMPLEMENTATION OF A NATIONAL COLORECTAL CANCER SCREENING PROGRAM AMONG PRIMARY CARE PHYSICIANSIN PUERTO RICO. *Gastroenterology*. 2019;156(6):S809-S809.
Reason for exclusion: Wrong study design
Pozo Parilli JC, Méndez Castro M, Pinto Plata V, Gómez LG, Ott Itriago S. Tumores de colon: experiecnia en un Centro Clínico de Caracas. *Gen*. 1994;48(1):19-24.
Reason for exclusion: Different setting
Rendon RF, Carrillo YB, Jacques J, et al. SCREENING COLONOSCOPY IN A NORTHWESTERN POPULATION IN MEXICO: BARRIERS AND FACTORS RELATED TO THE PROCEDURE IN AVERAGE RISK PATIENTS. *Gastroenterology*. 2017;152(5):S529-S529.
Reason for exclusion: Different outcome
Rivera G, Imbert AL, Bird J, et al. Yield of Fecal Immunohistochemical Test (FIT) for Colorectal Cancer Screening at the VA Caribbean Healthcare System: 1949. *Official journal of the American College of Gastroenterology| ACG*. 2012;107:S794.
Reason for exclusion: Different patient population
Rivera G, Imbert AL, Bird J, et al. Yield of Fecal Immunohistochemical Test (FIT) for Colorectal Cancer Screening at the VA Caribbean Healthcare System. *American Journal of Gastroenterology*. 2012;107:S794-S794. doi:10.14309/00000434-201210001-01949
Reason for exclusion: Duplicate data
Silva ACB, Vicentini MFB, Mendoza EZ, et al. Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center. *Current Problems in Cancer*. 2019;43(5):477-486. doi:10.1016/j.currproblcancer.2019.01.009
Reason for exclusion: Different outcome
Tchekmedyian A, Messuti A, Richelli R, et al. Colorectal Cancer Screening and Post-polypectomy Follow-up. Results from a National Survey in Uruguay: 1467. *Official journal of the American College of Gastroenterology| ACG*. 2009;104:S551-S552.
Reason for exclusion: Different patient population

Tchekmedyian A, Messuti A, Richelli R, et al. Colorectal Cancer Screening and Post-polypectomy Follow-up. Results from a National Survey in Uruguay. *American Journal of Gastroenterology*. 2009;104:S551-S552. doi:10.14309/00000434-200910003-01467
Reason for exclusion: Duplicate data
Vega Sánchez H, Jiménez Mesa G, González-Carbajal M, Grá Ormas B. Pesquisaje de lesiones premalignas y malignas de colon mediante sangre oculta en heces fecales. *Rev cuba cir*. 1993;32(2):131-7.
Reason for exclusion: Wrong study design

Wrong study design: Studies that do not meet the specific design requirements outlined in the inclusion criteria (i.e. Studies focusing in general colorectal health without specifically focusing on screening programs, or incidence, mortality and survival studies).

eTable 3. Risk of bias using the New Castle Ottawa Scale for Comparative Studies.

First Author	Year	Country	Adapted NOS quality assessment.			Total Score	Risk of bias
			Selection	Comparability	Exposure or outcome		
Fenocchi et al.	2006	Uruguay	****	**	***	9	Low
Garcia-Osogobio et al.	2015	Mexico	****	*	***	8	Low
Galvez-Rios et al.	2020	Mexico	****	*	**	7	Medium
Averbach et al.	2021	Brazil	****	**	**	8	Low
Braga et al.	2017	Brazil	**	*	***	6	Medium
Ruiz et al.	2021	Argentina	****	*	***	8	Low
Silva et al.	2011	Chile	**	*	***	6	Medium
Teixeira et al.	2017	Brazil	***	*	***	7	Medium
Okada et al.	2015	Chile	****	*	***	8	Low
Guimaraes et al.	2021	Brazil	****	**	***	9	Low
Lopez-Kostner et al.	2012	Chile	****	*	***	8	Low
Alfaro-Seguro et al.	2020	Costa Rica	****	**	**	9	Low
Fernandez et al.	2021	Argentina	****	*	**	7	Medium
Manzano-Robleda et al.	2020	Mexico	****	**	**	8	Low
Remes-Troche et al.	2020	Mexico	****	*	**	7	Medium
Rettally	2008	Panama	****	*	**	7	Medium
Fenocchi et al.	2015	Uruguay	****	**	**	8	Low

Note: The components listed above generate a total sum score for assessing risk of bias for each study. Total sum scores range from 0 to 9 points. Studies were grouped into ‘low risk of bias’ (8-9 points), ‘moderate risk of bias’ (5-7 points) or ‘high risk of bias’ (1-4 points). Comparability specifically referred to comparability between subjects in both outcome groups—i.e. control for confounding. We retained the original language from validation studies, even though all studies in our review only had one intervention group (without comparison group). The selection category also did not include the ‘ascertainment of exposure’ portion, because all studies included only intervention arms (no control groups).

eTable 4. Strategies for sampling and recruitment of included studies.

*Recruitment modes: Personal – direct interaction between study or healthcare personnel and potential subjects "face-to-face interaction"; Non-personal – not requiring direct face-to-face interaction [§]

Study characteristics				Sampling			Recruitment				
Author	**Year**	**Country**	**Study type**	**Sampling**	**Eligibility age**	**Risk of CRC**	**Recruitment location**	**Recruitment Mode[b]**	**Face-face**	**Letter/ e-mail**	**Media**
Fenocchi et al.	2006	Uruguay	Prospective	Voluntary response	>50	Average	Community	Media			X
Rettally	2008	Panama	Retrospective	Convenience	>50	Increased	Community	NR			
Silva et al.	2011	Chile	Prospective	Voluntary response	>50	Increased	Community	Personal/Media		X	X
Lopez-Kostner et al.	2012	Chile	Prospective	Voluntary response	>50	Average	CHC (Clinic)	Personal	X		
Fenocchi et al.	2015	Uruguay	Prospective	Population-based	>50	Average[a]	Hospital	NR			
Garcia-Osogobio et al.	2015	Mexico	Prospective	Convenience	40-79	Average	Workplace	Media			X
Braga et al.	2017	Brazil	Cross-sectional	Population-based	50-70	Elevated	CHC (Clinic)	Personal	X		
Teixeira et al.	2017	Brazil	Prospective	Population-based	50-75	Average[a]	CHC (Clinic)	Personal	X		
Alfaro-Seguro et al.	2020	Costa Rica	Prospective	Population-based	50-75	Average	Community	Personal	X		
Galvez-Rios et al.	2020	Mexico	Prospective	Voluntary response	>50	Average[a]	Community	Media			X
Manzano-Robleda et al.	2020	Mexico	Prospective	Convenience	50-75	Average	Workplace	Media			X
Okada et. Al	2020	Chile	Prospective	Population-based	NR	Increased	Hospital	Personal/Media			X
Remes-Troche et al.	2020	Mexico	Prospective	Voluntary response	>50	Average	Community	Media			X
Averbach et al.	2021	Brazil	Prospective	Population-based	50-70	Average	Hospital	Personal	X		
Fernandez et al.	2021	Argentina	Prospective	Convenience	50-75	Average	Hospital	Personal/Media	X		X
Guimaraes et al.	2021	Brazil	Cross-sectional	Convenience	50-65	Average	CHC and Health Fairs	Personal	X		
Ruiz et al.	2021	Argentina	Retrospective	Convenience	50-75	Average[a]	CHC (Clinic)	Personal	X		

Family history Not reported or effort not made to exclude. [b] Recruitment strategies included media advertisement only (n=5), personal invitation (n=7), combination of personal and media (n=3), and unspecified (n=2). Media modes of recruitment included radio and TV advertisements, posters in public and private institutions, and brochure distribution. "Personal" recruitment was carried out by healthcare professionals, community health workers/ navigators (CHW), or researchers, via in-person encounters or using individually addressed letters and/or emails. In-person encounters included clinics or hospitals (opportunistically when they visited for reasons other than screening; n= 9), or community settings (public places and own homes [n=6] or workplace [n=2]).

eTable 5. Univariate Meta regression

	Adenoma Detection Rate			Advanced Adenoma Detection Rate			CRC Detection Rate		
Moderator	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value
Age (mean)	0.004	-0.071 to 0.078	0.926	0.090	-0.043 to 0.224	0.185	**0.045**	**0.015 to 0.076**	**0.004**
CRC Family History (%)	-0.002	-0.010 to 0.007	0.670	-0.026	-0.0719 to 0.191	0.256	-0.0011	-0.005 to 0.005	0.963
Male (%)	**-0.032**	**-0.057 to -0.007**	**0.011**	**-0.036**	**-0.052 to -0.212**	**<0.001**	-0.010	-0.026 to 0.007	0.243
Sample Size									
Sample Size 1000-10,000	**0.483**	**0.027 to 0.937**	**0.038**	0.020	-0.556 to 0.597	0.945	-0.004	-0.039 to 0.382	0.984
Sample Size >10,000	-0.146	-0.594 to 0.302	0.523	-0.183	-0.753 to 0.388	0.533	-0.055	-0.433 to 0.325	0.775
Participation Rate	0.013	-0.002 to 0.029	0.086	0.007	-0.009 to 0.022	0.390	0.002	-0.008 to 0.013	0.681
FIT Positivity Rate	-0.023	-0.058 to 0.123	0.202	-0.003	-0.042 to 0.035	0.877	0.005	-0.019 to 0.029	0.771
Colonoscopy follow-up	0.006	-0.003 to 0.016	0.206	-0.001	-0.003 to 0.001	0.193	-0.001	-0.002 to 0.001	0.073
Publication year	-0.009	-0.056 to 0.036	0.677	-0.006	-0.041 to 0.294	0.732	0.001	-0.022 to 0.025	0.928
Region (South America)	0.118	-0.330 to 0.567	0.605	-0.104	-0.499 to 0.291	0.606	-0.119	-0.359 to 0.120	0.328
FIT cut-off									
50ng/ml	0.337	-0.267 to 0.941	0.274	**0.596**	**0.036 to 1.155**	**0.037**	0.182	-0.168 to 0.533	0.307
100ng/ml	0.237	-0.367 to 0.842	0.442	0.423	-0.145 to 0.992	0.144	0.057	-0.293 to 0.409	0.747
Funding									
Governmental	Ref			Ref			Ref		
Private	0.447	-0.237 to 1.132	0.200	0.453	-0.288 to 1.193	0.231	-0.056	-0.412 to 0.298	0.754
International	-0.036	-0.561 to 0.489	0.892	0.251	-0.287 to 0.788	0.361	0.126	-0.312 to 0.565	0.574
Risk of Bias: Medium	-0.195	-0.619 to 0.229	0.368	-0.037	-0.444 to 0.369	0.857	0.035	-0.206 to 0.277	0.772

eFigure 2. Participation Rate (FIT Given/FIT Returned) by region.



Random-effects REML model
Sorted by: year_pub author

eFigure 3. Participation Rate (FIT Given/FIT Returned) by Recruitment strategy



Random-effects REML model
Sorted by: year_pub author

eFigure 4. Participation Rate (FIT Given/FIT Returned) by Sample Size



Random-effects REML model
Sorted by: year_pub author

eFigure 5. Colonoscopy follow-up (colonoscopies performed after a positive FIT test).



Random-effects REML model
Sorted by: year_pub author

eFigure 6. Outcome ADR (Adenoma Detection Rate) per positive FIT test in FIT Based programs.



Note: Test of group differences p-value=0.97 excluding “Not reported” category.

eFigure 7. Outcome AADR (Advanced Adenomas Detection Rate) per positive FIT test in FIT Based programs.



Note: Test of group differences p-value=0.02 excluding “Not reported” category.

eFigure 8. Outcome CRCDR (Colorectal Cancer Detection Rate) per positive FIT test in FIT Based programs.



Note: Test of group differences p-value=0.86 excluding “Not reported” category.

eFigure 9. Yield of Colonoscopy: AADR (Advanced Adenomas Detection Rate). FIT programs



Random-effects REML model
Sorted by: year_pub author

eFigure 10. Yield of Colonoscopy: AADR (Advanced Adenomas Detection Rate). Direct-to-colonoscopy programs



eFigure 11. Yield of Colonoscopy: CRC-DR (Adenocarcinoma Detection Rate) by type of program



eFigure 12. Colonoscopy Quality Indicators: Cecal Intubation Rate



Random-effects REML model
Sorted by: year_pub author

eFigure 13. Colonoscopy Quality Indicators: Mean Withdrawal Time from cecum (mean, minutes)



Random-effects REML model
Sorted by: year_pub author

eFigure 14. Colonoscopy Quality Indicators: Adequate Bowel Preparation



Random-effects REML model
Sorted by: year_pub author

eFigure 15. Heterogeneity and Publication bias (small study effects) for FIT Based Studies

Heterogeneity	Publication Bias (small-study effects)
Participation Rates	
	 **Egger p-value=0.2010**
FIT positivity Rates	
	 **Egger p-value=0.8101**

eFigure 16. Heterogeneity and Publication bias (small study effects) for outcomes per positive FIT test in FIT based programs

Heterogeneity	Publication Bias (small-study effects)
Outcome per positive FIT test in FIT Based programs	
ADR (Adenoma Detection Rate).	
	 **Egger p-value=0.5886**
AADR (Advanced Adenomas Detection Rate).	
	 **Egger p-value=0.4609**
CRC Detection Rates	
	 **Egger p-value=0.5318**

eFigure 17. Heterogeneity and Publication bias (small study effects) for for outcomes in Direct-to-Colonoscopy programs

Heterogeneity	Publication Bias (small-study effects)
Colonoscopy Indicators	
ADR (Adenoma Detection Rate).	
	 **Egger p-value=0.6699**
AADR (Advanced Adenomas Detection Rate).	
	 **Egger p-value=.**
CRC Detection Rates	
	 **Egger p-value=0.4836**

eFigure 18. Heterogeneity and Publication bias (small study effects) for Colonoscopy quality indicators

Heterogeneity	Publication Bias (small-study effects)
Colonoscopy Quality Indicators	
Cecal Intubation Rate	
	 **Egger p-value=0.5315**
Mean Withdrawal Time	
	 **Egger p-value=0.2158**
Adequate Bowel Preparation	
	 **Egger p-value=0.1434**

eFigure 19. ADR (Adenomas Detection Rate) FIT programs by risk. Leave-one-out analysis.



Random-effects REML model
Sorted by: year_pub author

eFigure 20. ADR (Adenomas Detection Rate) FIT programs by FIT cut-off. Leave-one-out analysis.



*Leave-one-out analysis excluding Guimares et. al (2021) use of chromoendoscopy and Manzano-Robleda et. al (2020) use of endocuff.

eFigure 21. CRC (Adenocarcinoma Detection Rate) FIT programs. Leave-one-out analysis.



*Leave-one-out analysis excluding Guimares et. al (2021) use of chromoendoscopy and Manzano-Robleda et. al (2020) use of endocuff.

eFigure 22. ADR (Adenomas Detection Rate) FIT programs. Leave-one-out analysis.



Random-effects REML model
Sorted by: year_pub author

For each study, the displayed effect size corresponds to an overall effect size computed from a meta-analysis excluding that study. The leave-one-out forest plot also displays a vertical line at the overall effect size based on the complete set of studies (with no omission) to help detect influential studies. The omission of study 4 (Teixeira et al 2017), 5 (Alfaro-Seguro et al. 2020), 7 (Manzano-Robleda et al. 2020) 10 (Fernandez et al. 2021), 11 (Guimares et al. 2021) or 12 (Ruiz et. al 2021) have the largest influence (when compared with other studies) on the estimation of the overall effect size.

eFigure 23. AADR (Advanced Adenomas Detection Rate) FIT programs. Leave-one-out analysis.



Random-effects REML model
Sorted by: year_pub author

For each study, the displayed effect size corresponds to an overall effect size computed from a meta-analysis excluding that study. The leave-one-out forest plot also displays a vertical line at the overall effect size based on the complete set of studies (with no omission) to help detect influential studies. The omission of study 1 (Fenocchi et al. 2006), 5 (Alfaro-Seguro et al. 2020), and 7 (Manzano-Robleda et al, 2020) have the largest influence (when compared with other studies) on the estimation of the overall effect size.

eFigure 24. CRC (Adenocarcinoma Detection Rate) FIT programs. Leave-one-out analysis.



For each study, the displayed effect size corresponds to an overall effect size computed from a meta-analysis excluding that study. The leave-one-out forest plot also displays a vertical line at the overall effect size based on the complete set of studies (with no omission) to help detect influential studies. The omission of study 1 (Fenocchi et al. 2015) and 4 (Teixeira et al. 2017) have the largest negative effect on pooled CRC detection, while studies 5 (Alfaro-Seguro et al. 2020), and 9 (Remes-Troche et al. et al 2020) have the largest negative effect.